Acer Therapeutics Inc

NASDAQ:ACER   12:54:00 PM EDT
2.32
-0.05 (-2.11%)
Products

Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For NDA For Urea Cycle Disorders Treatment

Published: 10/06/2021 12:51 GMT
Acer Therapeutics Inc (ACER) - Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for Acer-001 to Treat Urea Cycle Disorders.
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for Acer-001 to Treat Urea Cycle Disorders.
Acer Therapeutics Inc - FDA Has Assigned a Prescription Drug User Fee Act (pdufa) Target Action Date of June 5, 2022.